乳腺癌100例临床预后的COX分析
摘要
目的:本研究旨在通过对新疆医科大学第二附属医院肿瘤外科女性乳腺癌患者的临床病理特点分析,探讨与预后有关的临床病理因素,为乳腺癌的临床预后判断提供一定的参考价值。方法:收集2003.3至2005.3我院及外院收治的100例有病理证实的女性乳腺癌患者,通过分析年龄,肿瘤大小,激素受体状态,绝经与否及腋窝淋巴结的情况对无瘤生存率以及3年5年生存率的影响。结果:采用SPSS15.0对数据进行统计分析,用寿命表法计算累积生存率,对年龄,肿瘤大小激素受体状态,绝经与否及腋窝淋巴结的情况指标采用Kaplan-Meier Log-rank检验先进行单因素分析,显示上述因素中年龄,是否绝经,ER及腋窝淋巴结对3年,5年无瘤生存期及3年5年生存率有影响。对上述有统计学意义的因素再进行cox回归分析,对3年,5年无瘤生存率及3年5年生存率有影响的因素均为年龄,绝经与否,腋窝淋巴结的个数,而肿瘤大小,PR,HER-2在本病例组中则是与预后无关的。结论:提示在本病例组中,年龄,ER,腋窝淋巴结的情况是乳腺癌的有价值的预后因素,没有证据表明肿瘤大小,PR,HER-2是无瘤生存率及5年生存率有价值的预后因素。
Objective: to investigate the value of clinical prognostic factors in 100 patients with breast cancer. Methods: The analysis was performed in 100 cases of the breast cancer treated from March , 2003 to March ,2005.The correlation of age, tumor size, axillary lymph node involvement, estrogen receptor status, progesterone receptor status, menopause status with prognosis of breast cancer was evaluated. Result: Kaplan-Meier Log-rank analysis revealed that 3/5-year overall survival rate and Disease free survival period of this group was significantly associated with age, menopause status ,axillary lymph node involvement, estrogen receptor status. Then cox analysis revealed that 3/5-year overall survival rate of these patients was significantly associated with age, menopause status , axillary lymph node involvement and tumor size,Progesterone receptor status, Human Epidermal growth factor Recepter-2 had no significant independent prognostic value. Conclusion: Our data demonstrated that age ,estrogen receptor status. axillary lymph node involvement were significant indicators of prognosis in breast cancer respectively and it was not demonstrated that tumor size, progesterone receptor status, human epidermal growth factor recepter-2 were significant prognostic factors.
Objective: to investigate the value of clinical prognostic factors in 100 patients with breast cancer. Methods: The analysis was performed in 100 cases of the breast cancer treated from March , 2003 to March ,2005.The correlation of age, tumor size, axillary lymph node involvement, estrogen receptor status, progesterone receptor status, menopause status with prognosis of breast cancer was evaluated. Result: Kaplan-Meier Log-rank analysis revealed that 3/5-year overall survival rate and Disease free survival period of this group was significantly associated with age, menopause status ,axillary lymph node involvement, estrogen receptor status. Then cox analysis revealed that 3/5-year overall survival rate of these patients was significantly associated with age, menopause status , axillary lymph node involvement and tumor size,Progesterone receptor status, Human Epidermal growth factor Recepter-2 had no significant independent prognostic value. Conclusion: Our data demonstrated that age ,estrogen receptor status. axillary lymph node involvement were significant indicators of prognosis in breast cancer respectively and it was not demonstrated that tumor size, progesterone receptor status, human epidermal growth factor recepter-2 were significant prognostic factors.
引文
[1] Halsted WS.The results of operation for the Johns Hopkins Hospital from June 1889 to January 1984 [D].Johns hopkins hosp.Bull, 1995,4:297.
[2] Andreassen M,D ahl-lversen,Sorensen B Extened exeresis of theregional lymph nodes atoperation for carcinoma of the breast and the result of a 5-year follow-up of the first 98 cases with romoval of the axillary as well as the supra clavicular glands [J].Acta Chir Stand. 1954 ,107:206-213.
[3] Subramaniam DSIsaaes C.Utilizing Prognostieand Predietive factors in breast cancer[J].Curr Treat O Ptions Oneol,2005,6:147-159.
[4]徐兵河主编.乳腺癌[M].北京:北京大学医学出版社,2005:87.
[5] Lantz PM,Mujahid M,Schwartz K,et al.The influence of race thnicity and individual social economic factors on breast cancer stage at diagnosis[J].Am J PublicHealth,2006,96(12):2173-2178.
[6]丁锦辉,黄先国,于冰.新疆地区维吾尔族女性乳腺癌的临床病理特征和预后分析[J].肿瘤研究与临床,2006,14(8):136-137.
[7]孙晗,吕明.41例回族妇女乳腺癌的临床分析[J].宁夏医学院学报,2001,23(1):11-13.
[8] Simon MS,Banerjee M,Crossley-MayH,et al.Racial differences in breast cancer survival in the Detroit MetroPolitan area[J].Breast Cancer ResTreat,2006,97(2): 149-155.
[9] Piccart-GebhartMJ,ProeterM,Leyland-JonesB,etal.)Trastuzumab after adjuvant ehemo thera pyinHER-2 positive breast caneer[J].NEng J Med,2005,353(16): 1659-1672.
[10] HallPA,Levison DA,Woods AL,et al.Proliferating cell nuclear antigen(PCNA) immunolocalzation in Paraffin sections:an index of cell Proliferation wit h evidence of deregulated exPression in some neo plasms[J].J Pat hol,1990,162(4): 285-294.
[11] Baker RR.Preoperative assessment of the patient with breast cancer[J].Surg Clin North Am,2002,64:1039-1050.
[12] Bart S.H.,Lee K.O.,H.Steven W.et al.Coregulation of EGFR/HER-2 levels and locations:Quantitative Analysis of HER2 over expression effects[J].Cancer Research, 2003,63(5):1130-1137.
[13] Eran R.N,Michael A.L.,Adele A.G.G.et al.Gene expression profiling of Neu-Induced mammary tumors from transgenic mice remealsgenetic and morphological similarities to CerbB 2 expression Human breast cancer[J]. Cancer Research, 2003,63(16): 4920-4926.
[14] David S,Robinson M.Rloe and extend of Lymphadenectomy for early breast cancer[J].Seninars in surgical oncology,1992,8:78.
[15] Aznavoorian S,Murphy AN,Stetle-Stevenson WG,et al Molecular aspects of tumorcell invasion and metastasis[J].Cancer,1993,71(4)1368-1371
[16]李晓莉,郭子恒,李玉莲.乳腺癌C-erbB-2、CD44v6、nm23表达与淋巴结转移及预后的关系[J].中华医学研究杂志,2003,3(2):111-112
[17]杨金巧,陈琳,幸天勇.乳腺癌中C-erbB-2癌基因与雌激素,孕激素受体和PS2的关系及其预后意义[J].四川大学学报(医学版),2004,35(3):334-336.
[18]李向东.C-erbB-2、ER和PR在乳腺癌中的表达与预后意义[J].现代肿瘤医学,2006,14(3):289-290.
[19] Howard EM,Lau SK,Lyles RH,et al Correlation and exPression of P53,HER-2 vascular endothelial growth factor(VEGF),and e-cadherin in a high-riskbreast-cancer PoPulation[J].Int J Clin Onco,2004,9(3):154.
[20] Hayes DF,Yamauchi H,Broadwater G,et al.Circulating HER-2/c-erbB-2/c-neu (HER-2) extracellular domain as a Prognostic factor in Patients with metastatic breast cancer:Cancer and Leukemia GrouP B Study 8662[J].Clin Cancer Res,2001,7(9):2703-2711.
[21] Allred DC,Harvey JM,Berardo M,et al. Prognostic and Predietive factors in Breast cancer by immunohistochemical analysis [J].Mod Pathol,1998,11:155 -168.
[22]张凡,张九鸿,刘军超等.乳腺癌ER、PR、CZethB22表达与病理类型相关性研究[J].河北北方学院学报(医学版),2005,22(3):s-12.
[23] Yamashita H,Kobayashi S,Iwase H,et al.Analysis of oncogenes and tumor suppressor genes in human breast cancer[J].J Pn J Cancer Res,1993,84:871-878.
[24] Hamilton A,Piceart M.The cont ribution of molecular markers to the Predietion of res Ponse in the treatment of breast cancer:a review of the literature on HER-2,P53 and BCL-2[J].Ann Oneol,2000,11:647-663.
[25] Iwase H,Ando Y,Ichihara S,etal. Immunohistoehemical analysis on Biological markers in ductal carceinoma in situ of the breast[J].Breast Cancer,2001,8:98-104.
[26] Kobayashi S,Iwase H,Itoh Y,et al.Es trogen receptor,C-erbB-2 and nm23/NDP kinase expression in the int raductal and in vasive components of human breast cancers[J].Jpn J Cancer Res,1992,83:859-865.
[27] Sandrucci U,Sorba Casalegno P,Percivale P.et al.Sentinel lymph node mapping and biopsy for breast cancer:a review of the literature relative to 4791 procedures [J].Tumori 1999,85:425~434.
[28]麦国丰.HER2,P53,ER,PR,EGFR,病理分期与乳腺癌患者生存期的相关性研究[D].第一军医大学,2003. 22(3):s-12.
[29]姚先莹.进一步提高乳腺癌病理诊断和预后的检测水平[J].中华病理学杂志,1994,23(6):323-326.
[30] Ross JS,Fletcher JA.The HER2/neu oncogene in breast cancer Prognostic factor Predictive factor and target for theraPy[J].Stem Cells,1998,16(6):413-428.
[31]黄志勇,陈海,孟凡清,等.乳腺癌P53,C-erbB-2基因蛋白,表皮生长因子受体与雌,孕激素受体的表达及其临床意义[J].实用肿瘤杂志,1996,11(3):112.
[32] Asa J. Nixon,Donna Neuberg,Daniel FHayes,et al .Relationship of Patient age to Pathologic features of the tumor and Prognosis Patients with stage 1or2breast cancer[J].J Clin Oneol,1994,12:888-894.
[33] Qinghua X,Vieente V,Vinee K,et al.Female patients with breast carcinoma age 30 years and younger have a poor prognosis[J].Caneer2001,92:2523-2528.
[34] A.Sidoni,A. Cavaliere,G. Bellezza,et al.Breast cancer in young women:clinic pathological features and biological specificity[J].The Breast cancer,2003, 12(4):247 -250.
[35] Oavid P,winchester MD.Breast cancer in young women[J].Surgical Clinics of North America,1996,76:279-285.
[36]张京泰,林本耀,左全和,等.雌激素受体水平测定与青年乳腺癌的预后[J].肿瘤防治研究,2000,27(4):296-297.
[37] Jesus MA,Fujita M,Kim KS,ea tl.Retro spcetive analysis of breastC ancer among young African American females[J].Breast Cancer ResTreat,2003,78(1): 81-87.
[38]陈伟国,李健文,朱丽,等.157例35岁以下女性乳腺癌的预后分析[J].肿瘤,2001,21:135-137.
[39]徐晓明,黄晓蓉,易瑛,等.78例青年人乳腺癌临床分析[J].四川肿瘤防治,2001,14:216-217.
[40] Winehester DP.Breast cancer in young women[J].Surg Clin North AIn,1996, 76(2): 279-87.
[41]陈伟国,李健文,朱丽.157例35岁以下女性乳腺癌的预后分析[J].肿瘤,2001 (2):60-62.
[42] Colleoni M,Rotmensz N,Robertson C,et al.very young women(<35years) with operable breast cancer:Features of disease at presentation[J].Annoneol, 2002,13 (2): 273-9.
[43] Nixon J,Neuberg D,Hayes DF,et al.Relationship of Patient age to Pathologicfeatures of the tumor and prognosis for Patients with stage I or II breast cancer[J].J Clinoneol,1994,12(5):888-94.
[44] Yildirim E,DalgicT,Berberoglu U. Prognostic significance of young age in breast cancer[J].J Surg oneol,2000,74(4):267-72.
[45] Colleoni M,Potmensz N,Robertson C,etal.Very young women(<35 years)with operable breast cancer: features of disease at presentation[J].Ann Oncology 2002,13(2): 273~279.
[46] Kothari AS,Beechey-Newman N,Arrigo C,et al.Breast carcinoma in women age 25 years or less[J].Cancer2002,94(3):606~614.
[47] Vorgias G,Koukouras D,Paleogiannoi V,et al.Prognostic significance of factors affecting disease free interval and overall survival for Stage breast cancer inGreece.A multivariate cohort study[J].Eur J Obstet Gynecol Reprod Biol 2001,95(1):100~104.
[48] Cianfroeea M,Goldstein LJ..Prognostic and Predictive factors in early-stage breast cancer[J].oneologist,2004,9(6):606-16.
[49] Traina A,Agostara B,Marasa L,et al.HER-2/neu expression in relation to clinicopathologic features of breast cancer Patients[J].Ann NYA ead Sei, 2006,1089:159-67.
[50] Menard S,Balsari A,Casalini P,et al.Her-2 positive breast carcinomasasa particular subset with peculiar relinieal behaviors[J].Clin Cancer Res,2002,8(2):520-5.
[51] Haybittle JL,Blamey RW,Elston CW et al.A prognostic index in primary breast cancer[J].Br J. Cancer1982,45:361~366.
[52]杨万才,陈荣清,千新来,等.乳腺癌患者妊娠次数与腋窝淋巴结转移关系的研究[J].中原医刊,1994,21(6):9-10.
[53]艾合买提江,吐尔伊力木,王闽全,阿地力·艾买提,等.乳腺癌腋窝淋巴结转移的高危临床因素预测[J].新疆医科大学报2004,27(5):474-476.
[54] NemotoT,NatajrajanN,Bewani R,et al.Breast cancer in the medial half.Results of 1978 National Survey of the America College of Surgeons[J]. Caneer,1983,51(8): 1333-8.
[55] FisherB,BauerM,Wiekerham DL,et al.Relation of number of Positive axillary nodes to the Prognosis of patients with primary breast cancer[J].An NSAB Pupdate. Caneer,1983,52(9):1551-7.
[1] Zucali R,Mariani L,Marubini E,et al.Early breast cancer:Evaluation of the prognostic role of the site of the primary tumor[J].JClin Oncol, 1998,16:1363– 1366.
[2] Fisher B.The evolution of paradigms for the management of breast cancer: apersonal perspective[J] .Cancer Res,1992,52(9):2371-2383.
[3] Fisher B.Systemic chemotherapy as an adjuvant to surgery intreatment of breast cancer[J].Cancer,1969,24:1286-1289.
[4] Van Dongen J A,Bartelink H,Rentiman lS,et al.Randomized clinical trial to assess the value of breast conserving therapy instage I and II breast cancer: EORTC10801 trial[J].J Natl Cancer Inst,1992,11:15-18.
[5] Blichter Toft M,Rose C,Andersen J A,et al.Danish randomized trial comparing breast conservation therapy with mastectomy:six years of life analysis table[J].J Natl Cancer Inst Monogr,1992,11:19.
[6] Polgar C,Fodor J,MajorT,et al.Radiotherapy confined to the tumor bed following breast conserving surgery currentstatus, controversies,and future projects[J].Onkol, 2002, 178(11):597.
[7] Boreger J,Kemperman H,HartA,et al.Riskfactor sinbreast conservation therapy[J].J Clin Oncol,1994,12(4):653.
[8]张保宁,余子豪.乳腺癌保乳手术的几个关键问题[J]中华肿瘤杂志,2001,23: 523 -524.
[9]欧阳涛.当代乳腺癌诊断和治疗理念的变化趋势[J].中华病理学杂志, 2007, 36(4):217-219.
[10] Newman LA,Kuerer HM.Advances in breast conservation therapy[J].J Clin Oncol, 2005,23(8):1685-1697.
[11] Touboul E,Buffat L,Belkacemi Y,et al.Local recurrences and distant metastases after breast-conserving surgery and radiation therapy for early breast cancer[J]. Int J Radiat Oncol Biol Phys, 1999, 43(1):25-38.
[12] Morrow M,Strom E,Basselt LW,et al.Standard for breast conservation therapy in the management of invasive breast carcinoma[J].CA Cancer J Clin,2002, 52(5): 277-300.
[13] Voogd A,Peterse J,Crommelin M,et al.Histological determinations for different types of local recurrence after breast-conserving therapy of invasive breast cancer:Dutch study group on local recurrence after breast conservation(BORST)[J].Eur,J Cancer, 1999, 35 (13): 1828.
[14]邵志敏.乳腺癌外科治疗发展趋势[J].外科理论与实践,2006,11(2):89-91.
[15]赵红梅,雷玉涛,侯宽永,等.乳腺癌伴Paget病临床诊治分析-特殊临床表现报告[J].中国微创外科杂志,2004,4(4):290-291.
[16] Fisher B,Anderson S,Bryant J,et al.Twenty year follow up of a randomized trial comparing total mastectomy,lumpectomy,and lumpectomy plus irradiation for the treatment of invasive breast cancer[J].N Engl J Med,2002,347:1233-1241.
[17] Liljegren G,Holmberg L,Bergh J,et al.10 Year results after sector resection with orwithout postoperative radiotherapy for stage I breast cancer:a randomized trial[J].J Clin Oncol,1999,17:2326-2333.
[18] Houghton J,Potyka I,Tobias J,et al.Prophylactic radiotherapy following surgery for early breast cancer-Is the benefit mainly in patients with involved margins?Results from a Cancer Research Campaign Trial[J].Proc Am Soc Clin Oncol,2001,20:25a.
[19] Harris JR,Lippman ME,Morrow M,et al.Diseases of the breast[C].3rd ed. Philadelphia: Lippincott Williams&Wilkins,2004:719-744.
[20] Taylor CW,Green SS,Dalton WS,et al.Muticenter randomized clinical trial of goserelin versus surgical overiectomy in pre-menopausal patients with receptor–positive metastatic breast cancer[J].J Clin Oncol,1998,16(3):994-999.
[21] Nabholtz JM,Buzdar A,Pollak M,et al.Anastrozole is superior totamoxifen as first-line therapyfor advanced breast cancer in postmenopausal women:results of a North American multicen-ter randomized trial[J].J Clin Oncol,2000,18 (22):3758-3767.
[22] Bonneterre J,Thurlimann B,Robertson JF,et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast can-cer in 668 postmenopausal women:result of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study[J].J Clin Oncol, 2000,18(22): 3748-3757.
[23]王佳玉,徐兵河.乳腺癌内分泌治疗新药fulvestrant临床研究进展[J].癌症进展杂志,2005,3(4):342-344.
[24] Fisher B,Dignam J,Bryant J,et al.Five versus more than five years of tamoxifen therapy for lymph node-negative breast cancer. updated fin dings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial[J].J Natl Cancer Inst,2001, 93:684~690.
[25] Boccardo F.Rubagotti A,Puntoni M,et al.Switching to anas-trozole versus continued tamoxifen treatment of early breast cancer: Preliminar yresults ofthe Italian Tamoxifen Anastrozole (ITA) Trial[J]. J Clin Oncol,2005,23:5138-5147.
[26] Coombes RC,Hall E,Snowdon C,et al.A randomized trial of exemestane after two to three years of tamoxifen therapy on postmenopausal women with primary breast cancer[J].N Engl J Med,2004,350:1081-1092.
[27] Ellis MJ,Ma C.Letrozole in the neoadjuvant setting:the P024 trial[J].Breast Cancer Res Treat,2007,105 Suppl 1:33-43.
[28] Milla I,Rallo L,Puig-Gali M,et al.Anastrozole (A) as neoad-juant (NEO) therapy for hormone-dependent locally advanced breast cancer (LABC)in postmeno pausal (PM) patient[J].Proc Am Soc Clin Oncol,2002, 21:40a.
[29] Macaskill EJ,RenshawL,Dixon JM,et al.Neoadjuvant use of hormonal therapy in elderly patients with early or locally advanced hormone receptor-positive breast cancer[J].Oncologist, 2006, 11(10):1081-1088.
[30]沈坤炜,沈镇宙.重视乳腺癌的综合治疗[J].中国实用外科杂志,2003, 23 (10): 577.
[31]张保宁,宣立学,王仲照.乳腺癌综合治疗的现状与展望[J].中国实用外科杂志, 2006,26(4):243-244.
[32]张斌.正确理解乳腺癌的新概念提高乳腺癌综合治疗水平[J].中国实用外科杂志,2006,26(4):246-247.
[2] Andreassen M,D ahl-lversen,Sorensen B Extened exeresis of theregional lymph nodes atoperation for carcinoma of the breast and the result of a 5-year follow-up of the first 98 cases with romoval of the axillary as well as the supra clavicular glands [J].Acta Chir Stand. 1954 ,107:206-213.
[3] Subramaniam DSIsaaes C.Utilizing Prognostieand Predietive factors in breast cancer[J].Curr Treat O Ptions Oneol,2005,6:147-159.
[4]徐兵河主编.乳腺癌[M].北京:北京大学医学出版社,2005:87.
[5] Lantz PM,Mujahid M,Schwartz K,et al.The influence of race thnicity and individual social economic factors on breast cancer stage at diagnosis[J].Am J PublicHealth,2006,96(12):2173-2178.
[6]丁锦辉,黄先国,于冰.新疆地区维吾尔族女性乳腺癌的临床病理特征和预后分析[J].肿瘤研究与临床,2006,14(8):136-137.
[7]孙晗,吕明.41例回族妇女乳腺癌的临床分析[J].宁夏医学院学报,2001,23(1):11-13.
[8] Simon MS,Banerjee M,Crossley-MayH,et al.Racial differences in breast cancer survival in the Detroit MetroPolitan area[J].Breast Cancer ResTreat,2006,97(2): 149-155.
[9] Piccart-GebhartMJ,ProeterM,Leyland-JonesB,etal.)Trastuzumab after adjuvant ehemo thera pyinHER-2 positive breast caneer[J].NEng J Med,2005,353(16): 1659-1672.
[10] HallPA,Levison DA,Woods AL,et al.Proliferating cell nuclear antigen(PCNA) immunolocalzation in Paraffin sections:an index of cell Proliferation wit h evidence of deregulated exPression in some neo plasms[J].J Pat hol,1990,162(4): 285-294.
[11] Baker RR.Preoperative assessment of the patient with breast cancer[J].Surg Clin North Am,2002,64:1039-1050.
[12] Bart S.H.,Lee K.O.,H.Steven W.et al.Coregulation of EGFR/HER-2 levels and locations:Quantitative Analysis of HER2 over expression effects[J].Cancer Research, 2003,63(5):1130-1137.
[13] Eran R.N,Michael A.L.,Adele A.G.G.et al.Gene expression profiling of Neu-Induced mammary tumors from transgenic mice remealsgenetic and morphological similarities to CerbB 2 expression Human breast cancer[J]. Cancer Research, 2003,63(16): 4920-4926.
[14] David S,Robinson M.Rloe and extend of Lymphadenectomy for early breast cancer[J].Seninars in surgical oncology,1992,8:78.
[15] Aznavoorian S,Murphy AN,Stetle-Stevenson WG,et al Molecular aspects of tumorcell invasion and metastasis[J].Cancer,1993,71(4)1368-1371
[16]李晓莉,郭子恒,李玉莲.乳腺癌C-erbB-2、CD44v6、nm23表达与淋巴结转移及预后的关系[J].中华医学研究杂志,2003,3(2):111-112
[17]杨金巧,陈琳,幸天勇.乳腺癌中C-erbB-2癌基因与雌激素,孕激素受体和PS2的关系及其预后意义[J].四川大学学报(医学版),2004,35(3):334-336.
[18]李向东.C-erbB-2、ER和PR在乳腺癌中的表达与预后意义[J].现代肿瘤医学,2006,14(3):289-290.
[19] Howard EM,Lau SK,Lyles RH,et al Correlation and exPression of P53,HER-2 vascular endothelial growth factor(VEGF),and e-cadherin in a high-riskbreast-cancer PoPulation[J].Int J Clin Onco,2004,9(3):154.
[20] Hayes DF,Yamauchi H,Broadwater G,et al.Circulating HER-2/c-erbB-2/c-neu (HER-2) extracellular domain as a Prognostic factor in Patients with metastatic breast cancer:Cancer and Leukemia GrouP B Study 8662[J].Clin Cancer Res,2001,7(9):2703-2711.
[21] Allred DC,Harvey JM,Berardo M,et al. Prognostic and Predietive factors in Breast cancer by immunohistochemical analysis [J].Mod Pathol,1998,11:155 -168.
[22]张凡,张九鸿,刘军超等.乳腺癌ER、PR、CZethB22表达与病理类型相关性研究[J].河北北方学院学报(医学版),2005,22(3):s-12.
[23] Yamashita H,Kobayashi S,Iwase H,et al.Analysis of oncogenes and tumor suppressor genes in human breast cancer[J].J Pn J Cancer Res,1993,84:871-878.
[24] Hamilton A,Piceart M.The cont ribution of molecular markers to the Predietion of res Ponse in the treatment of breast cancer:a review of the literature on HER-2,P53 and BCL-2[J].Ann Oneol,2000,11:647-663.
[25] Iwase H,Ando Y,Ichihara S,etal. Immunohistoehemical analysis on Biological markers in ductal carceinoma in situ of the breast[J].Breast Cancer,2001,8:98-104.
[26] Kobayashi S,Iwase H,Itoh Y,et al.Es trogen receptor,C-erbB-2 and nm23/NDP kinase expression in the int raductal and in vasive components of human breast cancers[J].Jpn J Cancer Res,1992,83:859-865.
[27] Sandrucci U,Sorba Casalegno P,Percivale P.et al.Sentinel lymph node mapping and biopsy for breast cancer:a review of the literature relative to 4791 procedures [J].Tumori 1999,85:425~434.
[28]麦国丰.HER2,P53,ER,PR,EGFR,病理分期与乳腺癌患者生存期的相关性研究[D].第一军医大学,2003. 22(3):s-12.
[29]姚先莹.进一步提高乳腺癌病理诊断和预后的检测水平[J].中华病理学杂志,1994,23(6):323-326.
[30] Ross JS,Fletcher JA.The HER2/neu oncogene in breast cancer Prognostic factor Predictive factor and target for theraPy[J].Stem Cells,1998,16(6):413-428.
[31]黄志勇,陈海,孟凡清,等.乳腺癌P53,C-erbB-2基因蛋白,表皮生长因子受体与雌,孕激素受体的表达及其临床意义[J].实用肿瘤杂志,1996,11(3):112.
[32] Asa J. Nixon,Donna Neuberg,Daniel FHayes,et al .Relationship of Patient age to Pathologic features of the tumor and Prognosis Patients with stage 1or2breast cancer[J].J Clin Oneol,1994,12:888-894.
[33] Qinghua X,Vieente V,Vinee K,et al.Female patients with breast carcinoma age 30 years and younger have a poor prognosis[J].Caneer2001,92:2523-2528.
[34] A.Sidoni,A. Cavaliere,G. Bellezza,et al.Breast cancer in young women:clinic pathological features and biological specificity[J].The Breast cancer,2003, 12(4):247 -250.
[35] Oavid P,winchester MD.Breast cancer in young women[J].Surgical Clinics of North America,1996,76:279-285.
[36]张京泰,林本耀,左全和,等.雌激素受体水平测定与青年乳腺癌的预后[J].肿瘤防治研究,2000,27(4):296-297.
[37] Jesus MA,Fujita M,Kim KS,ea tl.Retro spcetive analysis of breastC ancer among young African American females[J].Breast Cancer ResTreat,2003,78(1): 81-87.
[38]陈伟国,李健文,朱丽,等.157例35岁以下女性乳腺癌的预后分析[J].肿瘤,2001,21:135-137.
[39]徐晓明,黄晓蓉,易瑛,等.78例青年人乳腺癌临床分析[J].四川肿瘤防治,2001,14:216-217.
[40] Winehester DP.Breast cancer in young women[J].Surg Clin North AIn,1996, 76(2): 279-87.
[41]陈伟国,李健文,朱丽.157例35岁以下女性乳腺癌的预后分析[J].肿瘤,2001 (2):60-62.
[42] Colleoni M,Rotmensz N,Robertson C,et al.very young women(<35years) with operable breast cancer:Features of disease at presentation[J].Annoneol, 2002,13 (2): 273-9.
[43] Nixon J,Neuberg D,Hayes DF,et al.Relationship of Patient age to Pathologicfeatures of the tumor and prognosis for Patients with stage I or II breast cancer[J].J Clinoneol,1994,12(5):888-94.
[44] Yildirim E,DalgicT,Berberoglu U. Prognostic significance of young age in breast cancer[J].J Surg oneol,2000,74(4):267-72.
[45] Colleoni M,Potmensz N,Robertson C,etal.Very young women(<35 years)with operable breast cancer: features of disease at presentation[J].Ann Oncology 2002,13(2): 273~279.
[46] Kothari AS,Beechey-Newman N,Arrigo C,et al.Breast carcinoma in women age 25 years or less[J].Cancer2002,94(3):606~614.
[47] Vorgias G,Koukouras D,Paleogiannoi V,et al.Prognostic significance of factors affecting disease free interval and overall survival for Stage breast cancer inGreece.A multivariate cohort study[J].Eur J Obstet Gynecol Reprod Biol 2001,95(1):100~104.
[48] Cianfroeea M,Goldstein LJ..Prognostic and Predictive factors in early-stage breast cancer[J].oneologist,2004,9(6):606-16.
[49] Traina A,Agostara B,Marasa L,et al.HER-2/neu expression in relation to clinicopathologic features of breast cancer Patients[J].Ann NYA ead Sei, 2006,1089:159-67.
[50] Menard S,Balsari A,Casalini P,et al.Her-2 positive breast carcinomasasa particular subset with peculiar relinieal behaviors[J].Clin Cancer Res,2002,8(2):520-5.
[51] Haybittle JL,Blamey RW,Elston CW et al.A prognostic index in primary breast cancer[J].Br J. Cancer1982,45:361~366.
[52]杨万才,陈荣清,千新来,等.乳腺癌患者妊娠次数与腋窝淋巴结转移关系的研究[J].中原医刊,1994,21(6):9-10.
[53]艾合买提江,吐尔伊力木,王闽全,阿地力·艾买提,等.乳腺癌腋窝淋巴结转移的高危临床因素预测[J].新疆医科大学报2004,27(5):474-476.
[54] NemotoT,NatajrajanN,Bewani R,et al.Breast cancer in the medial half.Results of 1978 National Survey of the America College of Surgeons[J]. Caneer,1983,51(8): 1333-8.
[55] FisherB,BauerM,Wiekerham DL,et al.Relation of number of Positive axillary nodes to the Prognosis of patients with primary breast cancer[J].An NSAB Pupdate. Caneer,1983,52(9):1551-7.
[1] Zucali R,Mariani L,Marubini E,et al.Early breast cancer:Evaluation of the prognostic role of the site of the primary tumor[J].JClin Oncol, 1998,16:1363– 1366.
[2] Fisher B.The evolution of paradigms for the management of breast cancer: apersonal perspective[J] .Cancer Res,1992,52(9):2371-2383.
[3] Fisher B.Systemic chemotherapy as an adjuvant to surgery intreatment of breast cancer[J].Cancer,1969,24:1286-1289.
[4] Van Dongen J A,Bartelink H,Rentiman lS,et al.Randomized clinical trial to assess the value of breast conserving therapy instage I and II breast cancer: EORTC10801 trial[J].J Natl Cancer Inst,1992,11:15-18.
[5] Blichter Toft M,Rose C,Andersen J A,et al.Danish randomized trial comparing breast conservation therapy with mastectomy:six years of life analysis table[J].J Natl Cancer Inst Monogr,1992,11:19.
[6] Polgar C,Fodor J,MajorT,et al.Radiotherapy confined to the tumor bed following breast conserving surgery currentstatus, controversies,and future projects[J].Onkol, 2002, 178(11):597.
[7] Boreger J,Kemperman H,HartA,et al.Riskfactor sinbreast conservation therapy[J].J Clin Oncol,1994,12(4):653.
[8]张保宁,余子豪.乳腺癌保乳手术的几个关键问题[J]中华肿瘤杂志,2001,23: 523 -524.
[9]欧阳涛.当代乳腺癌诊断和治疗理念的变化趋势[J].中华病理学杂志, 2007, 36(4):217-219.
[10] Newman LA,Kuerer HM.Advances in breast conservation therapy[J].J Clin Oncol, 2005,23(8):1685-1697.
[11] Touboul E,Buffat L,Belkacemi Y,et al.Local recurrences and distant metastases after breast-conserving surgery and radiation therapy for early breast cancer[J]. Int J Radiat Oncol Biol Phys, 1999, 43(1):25-38.
[12] Morrow M,Strom E,Basselt LW,et al.Standard for breast conservation therapy in the management of invasive breast carcinoma[J].CA Cancer J Clin,2002, 52(5): 277-300.
[13] Voogd A,Peterse J,Crommelin M,et al.Histological determinations for different types of local recurrence after breast-conserving therapy of invasive breast cancer:Dutch study group on local recurrence after breast conservation(BORST)[J].Eur,J Cancer, 1999, 35 (13): 1828.
[14]邵志敏.乳腺癌外科治疗发展趋势[J].外科理论与实践,2006,11(2):89-91.
[15]赵红梅,雷玉涛,侯宽永,等.乳腺癌伴Paget病临床诊治分析-特殊临床表现报告[J].中国微创外科杂志,2004,4(4):290-291.
[16] Fisher B,Anderson S,Bryant J,et al.Twenty year follow up of a randomized trial comparing total mastectomy,lumpectomy,and lumpectomy plus irradiation for the treatment of invasive breast cancer[J].N Engl J Med,2002,347:1233-1241.
[17] Liljegren G,Holmberg L,Bergh J,et al.10 Year results after sector resection with orwithout postoperative radiotherapy for stage I breast cancer:a randomized trial[J].J Clin Oncol,1999,17:2326-2333.
[18] Houghton J,Potyka I,Tobias J,et al.Prophylactic radiotherapy following surgery for early breast cancer-Is the benefit mainly in patients with involved margins?Results from a Cancer Research Campaign Trial[J].Proc Am Soc Clin Oncol,2001,20:25a.
[19] Harris JR,Lippman ME,Morrow M,et al.Diseases of the breast[C].3rd ed. Philadelphia: Lippincott Williams&Wilkins,2004:719-744.
[20] Taylor CW,Green SS,Dalton WS,et al.Muticenter randomized clinical trial of goserelin versus surgical overiectomy in pre-menopausal patients with receptor–positive metastatic breast cancer[J].J Clin Oncol,1998,16(3):994-999.
[21] Nabholtz JM,Buzdar A,Pollak M,et al.Anastrozole is superior totamoxifen as first-line therapyfor advanced breast cancer in postmenopausal women:results of a North American multicen-ter randomized trial[J].J Clin Oncol,2000,18 (22):3758-3767.
[22] Bonneterre J,Thurlimann B,Robertson JF,et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast can-cer in 668 postmenopausal women:result of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study[J].J Clin Oncol, 2000,18(22): 3748-3757.
[23]王佳玉,徐兵河.乳腺癌内分泌治疗新药fulvestrant临床研究进展[J].癌症进展杂志,2005,3(4):342-344.
[24] Fisher B,Dignam J,Bryant J,et al.Five versus more than five years of tamoxifen therapy for lymph node-negative breast cancer. updated fin dings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial[J].J Natl Cancer Inst,2001, 93:684~690.
[25] Boccardo F.Rubagotti A,Puntoni M,et al.Switching to anas-trozole versus continued tamoxifen treatment of early breast cancer: Preliminar yresults ofthe Italian Tamoxifen Anastrozole (ITA) Trial[J]. J Clin Oncol,2005,23:5138-5147.
[26] Coombes RC,Hall E,Snowdon C,et al.A randomized trial of exemestane after two to three years of tamoxifen therapy on postmenopausal women with primary breast cancer[J].N Engl J Med,2004,350:1081-1092.
[27] Ellis MJ,Ma C.Letrozole in the neoadjuvant setting:the P024 trial[J].Breast Cancer Res Treat,2007,105 Suppl 1:33-43.
[28] Milla I,Rallo L,Puig-Gali M,et al.Anastrozole (A) as neoad-juant (NEO) therapy for hormone-dependent locally advanced breast cancer (LABC)in postmeno pausal (PM) patient[J].Proc Am Soc Clin Oncol,2002, 21:40a.
[29] Macaskill EJ,RenshawL,Dixon JM,et al.Neoadjuvant use of hormonal therapy in elderly patients with early or locally advanced hormone receptor-positive breast cancer[J].Oncologist, 2006, 11(10):1081-1088.
[30]沈坤炜,沈镇宙.重视乳腺癌的综合治疗[J].中国实用外科杂志,2003, 23 (10): 577.
[31]张保宁,宣立学,王仲照.乳腺癌综合治疗的现状与展望[J].中国实用外科杂志, 2006,26(4):243-244.
[32]张斌.正确理解乳腺癌的新概念提高乳腺癌综合治疗水平[J].中国实用外科杂志,2006,26(4):246-247.